Psoriatic Arthritis
Conference Coverage
Obesity might be targetable driver of psoriatic arthritis progression
MADRID – Two studies show how obesity correlates with greater psoriatic arthritis disease activity and disability and how substantial weight loss...
Conference Coverage
Ixekizumab surpasses adalimumab in PsA head-to-head study
MADRID –
From the Journals
Carotid ultrasound may aid cardiovascular risk stratification of patients with psoriatic disease
The study suggests that bedside ultrasound could be a valuable augmentation to traditional risk stratification in these patients.
From the Journals
Active psoriatic arthritis, ankylosing spondylitis linked to increase in adverse pregnancy outcomes
Women with psoriatic arthritis and ankylosing spondylitis generally have favorable pregnancy outcomes, but high disease activity during pregnancy...
From the Journals
Th17-associated cytokines, CRP fail as biomarkers for ustekinumab success in PsA
Baseline levels of IL-17A, IL-17F, IL-23, and C-reactive protein were not associated with response to ustekinumab in either skin or joints.
Latest News
EMA: Stop high-dose Xeljanz in certain patients
The temporary recommendation applies to all tofacitinib indications.
Conference Coverage
VA system lags in getting DMARDs to veterans with inflammatory arthritis
MADISON, WISC. – More than two-thirds of ankylosing spondylitis patients didn’t receive a DMARD in the first year...
From the Journals
Etanercept biosimilar SB4 a cost-effective alternative for psoriasis, PsA
Statistically significant improvement in symptom scores and significant cost savings of up to 63% achieved.
News from the FDA/CDC
Arthritis joint pain, inactivity vary greatly across U.S.
The Southeast has the highest rates of adults with severe joint pain and physical inactivity, the CDC reports.
Conference Coverage
Weight loss improves psoriatic arthritis
MAUI, HAWAII – A promising nondrug therapy for motivated obese psoriatic arthritis patients.
From the Journals
PsA patients had durable responses after 1 year of IV golimumab treatment
No new safety signals seen in follow-up.